Spirovant Sciences Doses First Patient in the SAAVe Phase 1/2 Clinical Trial of Its Investigational, Aerosol-Delivered Genetic Medicine for the Treatment of Cystic Fibrosis
Hand-out
Press Releases
November 14, 2024

Spirovant Sciences Doses First Patient in the SAAVe Phase 1/2 Clinical Trial of Its Investigational, Aerosol-Delivered Genetic Medicine for the Treatment of Cystic Fibrosis

SP-101, an AAV vector-based gene therapy delivered via inhalation, is being investigated in combination with doxorubicin, an augmenter to enhance transgene expression in the lungs

bradford

The Bradford Era

More by this Author
Local & Social